Extracellular Vesicle Therapy for Type 1 Diabetes

Research output: Contribution to journal › Review › Research › peer-review

Standard

Extracellular Vesicle Therapy for Type 1 Diabetes. / Soltani, Setareh; Mansouri, Kamran; Emami Aleagha, Mohammad Sajad; Moasefi, Narges; Yavari, Niloofar; Shakouri, Seyed Kazem; Notararigo, Sara; Shojaeian, Ali; Pociot, Flemming; Yarani, Reza.

In: Frontiers in Immunology, Vol. 13, 865782, 2022.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Soltani, S, Mansouri, K, Emami Aleagha, MS, Moasefi, N, Yavari, N, Shakouri, SK, Notararigo, S, Shojaeian, A, Pociot, F & Yarani, R 2022, 'Extracellular Vesicle Therapy for Type 1 Diabetes', Frontiers in Immunology, vol. 13, 865782. https://doi.org/10.3389/fimmu.2022.865782

APA

Soltani, S., Mansouri, K., Emami Aleagha, M. S., Moasefi, N., Yavari, N., Shakouri, S. K., Notararigo, S., Shojaeian, A., Pociot, F., & Yarani, R. (2022). Extracellular Vesicle Therapy for Type 1 Diabetes. Frontiers in Immunology, 13, [865782]. https://doi.org/10.3389/fimmu.2022.865782

Vancouver

Soltani S, Mansouri K, Emami Aleagha MS, Moasefi N, Yavari N, Shakouri SK et al. Extracellular Vesicle Therapy for Type 1 Diabetes. Frontiers in Immunology. 2022;13. 865782. https://doi.org/10.3389/fimmu.2022.865782

Author

Soltani, Setareh ; Mansouri, Kamran ; Emami Aleagha, Mohammad Sajad ; Moasefi, Narges ; Yavari, Niloofar ; Shakouri, Seyed Kazem ; Notararigo, Sara ; Shojaeian, Ali ; Pociot, Flemming ; Yarani, Reza. / Extracellular Vesicle Therapy for Type 1 Diabetes. In: Frontiers in Immunology. 2022 ; Vol. 13.

Bibtex

@article{3529548d9a2843488ac9a5a411e44531,
title = "Extracellular Vesicle Therapy for Type 1 Diabetes",
abstract = "Type 1 diabetes (T1D) is a chronic disorder characterized by immune-mediated destruction of pancreatic insulin-producing β-cells. The primary treatment for T1D is multiple daily insulin injections to control blood sugar levels. Cell-free delivery packets with therapeutic properties, extracellular vesicles (EVs), mainly from stem cells, have recently gained considerable attention for disease treatments. EVs provide a great potential to treat T1D ascribed to their regenerative, anti-inflammatory, and immunomodulatory effects. Here, we summarize the latest EV applications for T1D treatment and highlight opportunities for further investigation.",
keywords = "exosomes, extracellular vesicle, immunomodulation, therapy, type 1 diabetes, β-cell",
author = "Setareh Soltani and Kamran Mansouri and {Emami Aleagha}, {Mohammad Sajad} and Narges Moasefi and Niloofar Yavari and Shakouri, {Seyed Kazem} and Sara Notararigo and Ali Shojaeian and Flemming Pociot and Reza Yarani",
note = "Publisher Copyright: Copyright {\textcopyright} 2022 Soltani, Mansouri, Emami Aleagha, Moasefi, Yavari, Shakouri, Notararigo, Shojaeian, Pociot and Yarani.",
year = "2022",
doi = "10.3389/fimmu.2022.865782",
language = "English",
volume = "13",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Research Foundation",

}

RIS

TY - JOUR

T1 - Extracellular Vesicle Therapy for Type 1 Diabetes

AU - Soltani, Setareh

AU - Mansouri, Kamran

AU - Emami Aleagha, Mohammad Sajad

AU - Moasefi, Narges

AU - Yavari, Niloofar

AU - Shakouri, Seyed Kazem

AU - Notararigo, Sara

AU - Shojaeian, Ali

AU - Pociot, Flemming

AU - Yarani, Reza

N1 - Publisher Copyright: Copyright © 2022 Soltani, Mansouri, Emami Aleagha, Moasefi, Yavari, Shakouri, Notararigo, Shojaeian, Pociot and Yarani.

PY - 2022

Y1 - 2022

N2 - Type 1 diabetes (T1D) is a chronic disorder characterized by immune-mediated destruction of pancreatic insulin-producing β-cells. The primary treatment for T1D is multiple daily insulin injections to control blood sugar levels. Cell-free delivery packets with therapeutic properties, extracellular vesicles (EVs), mainly from stem cells, have recently gained considerable attention for disease treatments. EVs provide a great potential to treat T1D ascribed to their regenerative, anti-inflammatory, and immunomodulatory effects. Here, we summarize the latest EV applications for T1D treatment and highlight opportunities for further investigation.

AB - Type 1 diabetes (T1D) is a chronic disorder characterized by immune-mediated destruction of pancreatic insulin-producing β-cells. The primary treatment for T1D is multiple daily insulin injections to control blood sugar levels. Cell-free delivery packets with therapeutic properties, extracellular vesicles (EVs), mainly from stem cells, have recently gained considerable attention for disease treatments. EVs provide a great potential to treat T1D ascribed to their regenerative, anti-inflammatory, and immunomodulatory effects. Here, we summarize the latest EV applications for T1D treatment and highlight opportunities for further investigation.

KW - exosomes

KW - extracellular vesicle

KW - immunomodulation

KW - therapy

KW - type 1 diabetes

KW - β-cell

U2 - 10.3389/fimmu.2022.865782

DO - 10.3389/fimmu.2022.865782

M3 - Review

C2 - 35464488

AN - SCOPUS:85128616254

VL - 13

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

M1 - 865782

ER -

ID: 305713545